Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-64619178 |
Synonyms | |
Therapy Description |
JNJ-64619178 is a PRMT5 inhibitor that binds to and inhibits the S-adenosylmethionine (SAM) and substrate-binding regions of the PRMT5/MEP50 complex, potentially reducing dimethylation of target proteins such as SMD1/3 and resulting in tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 4859, PMID: 31312965). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-64619178 | JNJ64619178|JNJ 64619178 | PRMT5 Inhibitor 17 | JNJ-64619178 is a PRMT5 inhibitor that binds to and inhibits the S-adenosylmethionine (SAM) and substrate-binding regions of the PRMT5/MEP50 complex, potentially reducing dimethylation of target proteins such as SMD1/3 and resulting in tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 4859, PMID: 31312965). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03573310 | Phase I | JNJ-64619178 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | Active, not recruiting | USA | ISR | ESP | DEU | CAN | 0 |